Aclaris Therapeutics reports positive Phase 1b proof-of-concept results for ATI-052 in atopic dermatitis and asthma

Aclaris Therapeutics reported positive Phase 1b proof-of-concept primary analysis results for its anti-TSLP/IL-4Rα bispecific candidate ATI-052 in atopic dermatitis and asthma, showing rapid, durable skin and itch improvement, improved lung function and reduced airway inflammation. The results support prioritizing ATI-052 in eosinophilic esophagitis, with a Phase 2b trial expected to follow.

Detected & updated continuously · Source: Nebula